Aegis reissued their buy rating on shares of Heska (NASDAQ:HSKA) in a research note released on Tuesday, December 19th.
Several other research analysts have also recently issued reports on the company. BidaskClub raised Heska from a sell rating to a hold rating in a research note on Thursday, December 21st. Raymond James Financial reaffirmed a buy rating on shares of Heska in a research note on Monday, December 4th. B. Riley decreased their target price on Heska from $96.50 to $93.00 and set a neutral rating for the company in a research note on Friday, November 3rd. Canaccord Genuity initiated coverage on Heska in a research note on Thursday, October 5th. They set a buy rating and a $115.00 target price for the company. Finally, Zacks Investment Research cut Heska from a buy rating to a hold rating in a research note on Wednesday, October 4th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. Heska has an average rating of Hold and a consensus target price of $113.30.
Heska (NASDAQ:HSKA) traded down $2.59 during mid-day trading on Tuesday, hitting $78.48. The company had a trading volume of 50,886 shares, compared to its average volume of 58,068. Heska has a twelve month low of $75.21 and a twelve month high of $115.00. The firm has a market cap of $587.25, a price-to-earnings ratio of 41.09, a P/E/G ratio of 2.14 and a beta of 0.74.
Heska (NASDAQ:HSKA) last issued its earnings results on Thursday, November 2nd. The medical research company reported $0.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.37 by $0.03. Heska had a return on equity of 15.35% and a net margin of 10.67%. The firm had revenue of $31.40 million for the quarter, compared to analyst estimates of $36.10 million. During the same period last year, the company earned $0.45 earnings per share. The firm’s revenue for the quarter was down 6.0% on a year-over-year basis. research analysts forecast that Heska will post 2.03 earnings per share for the current year.
In related news, insider Michael J. Mcginley sold 7,826 shares of the stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $87.14, for a total value of $681,957.64. Following the completion of the sale, the insider now directly owns 106,771 shares of the company’s stock, valued at approximately $9,304,024.94. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 14.70% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in HSKA. Teachers Advisors LLC lifted its stake in Heska by 11.6% in the 1st quarter. Teachers Advisors LLC now owns 10,590 shares of the medical research company’s stock worth $1,112,000 after acquiring an additional 1,097 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of Heska during the 1st quarter worth about $5,853,000. Municipal Employees Retirement System of Michigan purchased a new stake in shares of Heska during the 2nd quarter worth about $154,000. Great West Life Assurance Co. Can purchased a new stake in shares of Heska during the 2nd quarter worth about $936,000. Finally, Texas Permanent School Fund raised its stake in shares of Heska by 80.3% during the 2nd quarter. Texas Permanent School Fund now owns 4,676 shares of the medical research company’s stock worth $477,000 after purchasing an additional 2,083 shares in the last quarter. 80.89% of the stock is owned by hedge funds and other institutional investors.
WARNING: “Heska’s (HSKA) “Buy” Rating Reiterated at Aegis” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/13/heska-hska-earns-buy-rating-from-aegis.html.
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.